Hypertrophic Cardiomyopathy: Overview of 2020 Guidelines and Future

In this CME, Timothy Wong, MD, MS, discusses how hypertrophic cardiomyopathy is diagnosed, genetic testing for it, therapeutic options, identifies the risk stratification criteria to identify patients at high risk for sudden cardiac death, and the updated guideline recommendations for sports participation in the settling of hypertrophic cardiomyopathy including the concept of shared decision.

Educational Objectives:

Upon Completion of this activity, participants should be able to:

  • Explain the process by which hypertrophic cardiomyopathy is diagnosed
  • Identify two uses of genetic testing for hypertrophic cardiomyopathy care
  • Recognize therapeutic options available for obstructive and nonobstructive hypertrophic cardiomyopathy, and the difference between myectomy and ablation
  • Identify risk stratification criteria to identify patients at high risk for sudden cardiac death
  • Follow updated guideline recommendations for sports participation in the setting of hypertrophic cardiomyopathy including the concept of shared decision.

Disclosures:

Dr. Wong has financial interests with the following entity or entities producing health care goods or services as indicated below:

  • Grant/Research Support: Site principal investigator Bristol Myers Squibb, Cytokinetics
  • Consultant: Unpaid consultant for Bristol Myers Squibb and Cytokinetics
  • Other: CME contributor to Projects in Knowledge

All presenters' disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above.  No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

Accreditation Statement:

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh designates enduring material activity for a maximum of .75 AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

For your credit transcript, please access our website 4 weeks post-completion at http://ccehs.upmc.com and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.

Release Date: 12/8/2021 | Last Modified On: 12/8/2021 | Expires: 12/8/2022


Published

December 8, 2021

Expires

December 8, 2022

Related Presenters

Timothy C. Wong, MD, MS

Timothy C. Wong, MD, MS

Director, UPMC Hypertrophic Cardiomyopathy Center

Full Profile